Survival analysis in familial ovarian cancer, a case control study

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 98, Issue 2, 2001, Pages 219-223

  Zweemer, Ronald P ^a   Verheijen, René H M ^a   Coebergh, Jan Willem W ^b   Jacobs, Ian J ^c   Van Diest, Paul J ^a   Gille, Johan J P ^a   Skates, Steven ^d   Menko, Fred H ^a   Ten Kate, Leo P ^a   Kenemans, Peter ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

BRCA1; BRCA2; Hereditary; Ovarian cancer; Survival

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ARTICLE; CASE CONTROL STUDY; FEMALE; GENETICS; HUMAN; MIDDLE AGED; MORTALITY; MUTATION; OVARY TUMOR; PEDIGREE; SURVIVAL RATE;

BRCA1 PROTEIN; BRCA2 PROTEIN; CASE-CONTROL STUDIES; FEMALE; GERM-LINE MUTATION; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PEDIGREE; SURVIVAL RATE;

EID: 10644229501     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-2115(01)00318-9     Document Type: Article

References (29)

1. Koper NP, Lambertus AL, Kiemeney, et al. Ovarian cancer incidence (1989-1991) and mortality (1954-1993) in The Netherlands. Obstet Gynecol 1996;88:387-93.
2. Balvert-Locht HR, Coebergh JWW, Hop WJC, et al. Improved prognosis of ovarian cancer in The Netherlands during the period 1975-1985: a registry-based study. Gynecol Oncol 1991;42:3-8.
3. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New Eng J Med 1996; 334:1-6.
4. ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;15:2183-93.
5. Coebergh JJW, van der Heijden LH, Janssen-Heijen MLG, editors. Cancer of the ovary, in Cancer incidence and survival in the Southeast of The Netherlands 1955-1994. Eindhoven: IKZ, 1995, p. 62-3.
6. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. Ca: Cancer J Clinicians 1995;45:8-30.
7. Brinkhuis M, Meijer GA, Baak JP. An evaluation of prognostic factors in advanced ovarian cancer. Eur J Obstet Gynecol Reprod Biol 1995;63:115-24.
8. Goff BA, Sainz de la Cuesta R, Muntz HG, et al. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 1996;60:412-7.
9. Zanetta G, Keeney GL, Cha SS, et al. Flow-cytometric analysis of deoxyribonucleic acid content in advanced ovarian carcinoma: its importance in long-term survival. Am J Obstet Gynecol 1996;175:1217-25.
10. Vergote IB, Kaern J, Abeler VM, et al. Analysis of prognostic factors in stage I epithelial ovarian carcinoma: importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse. Am J Obstet Gynecol 1993;169:40-52.
11. Kaern J, Trope CG, Kristensen GB, et al. Evaluation of deoxyribonucleic acid ploidy and s-phase fraction as prognostic parameters in advanced epithelial ovarian carcinoma: a prospective study. Am J Obstet Gynecol 1994;170:479-87.
12. Berchuck A, Kamel A, Whitaker R, et al. Overexpression of HER-2/ neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990;50:4087-91.
13. Geisler JP, Geisler HE, Wiemann MC, et al. Quantification of p53 in epithelial ovarian cancer. Gynecol Oncol 1997;66:435-8.
14. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
15. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789-92.
16. Lancaster JM, Wooster R, Mangion J, et al. BRCA2 mutations in primary breast and ovarian cancers. Nature Genet 1996;13:238-40.
17. Takahashi H, Chiu HC, Bandera CA, et al. Mutations of the BRCA2 gene in ovarian carcinomas. Cancer Res 1996;56:2738-41.
18. Zweemer RP, Verheijen RHM, Gille JJP, et al. Clinical and genetic evaluation of 30 ovarian cancer families. Am J Obstet Gynecol 1998;178:85-90.
19. Rubin SC, Benjamin I, Behbakht K, et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. New Eng J Med 1996;335:1413-6.
20. Petrij-Bosch A, Peelen T, van Vliet M, et al. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nature Genet 1997;17:341-5.
21. Takahashi H, Behbakht K, McGovern PE, et al. Mutation analysis of the BRCA1 gene in ovarian cancers. Cancer Res 1995;55:2998-3002.
22. Merajver SD, Pham TM, Caduff RF, et al. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nature Genet 1995;9:439-43.
23. Foster KA, Harrington P, Kerr J, et al. Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer. Cancer Res 1996;56:3622-5.
24. Narod S, Tonin P, Lynch H, et al. Histology of BRCA1-associated ovarian tumours. Lancet 1994;343:236.
25. Boyd J, Sonoda Y, Federici MG, et al. Clinicopathological features of BRCA-linked and sporadic ovarian cancer. JAMA 2000;283:2260-5.
26. Brunet JB, Narod SA, Tonin P, et al. BRCA1 mutations and survival in ovarian cancer. New Eng J Med 1997;336:1256.
27. Johannsson O, Ranstam J, Borg A, et al. Survival of BRCA1 breast and ovarian cancer patients: a population based study from Southern Sweden. J Clin Oncol 1998;16:397-404.
28. Verhoog LG, Brekelmans CTM, Seynaeve C, et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 1998;351:316-21.
29. Hogervorst FB, Cornelis RS, Bout M, et al. Rapid detection of BRCA1 mutations by the protein truncation test. Nature Genet 1995;10:208-12.